U.S. RESEARCH ROUNDUP- Amgen, Coupa Software, Zebra Technologies

Vontier

13/12/2022 07:16

Dec 13 (Reuters) - Wall Street securities analysts revised their ratings and price
targets on several U.S.-listed companies, including Amgen, Coupa Software and Zebra Technologies
on Tuesday. 
  HIGHLIGHTS        
     * Amgen Inc  AMGN.O : Piper Sandler raises target price to $299 from $297
     * Coupa Software Inc  COUP.O : RBC raises to sector perform from underperform
     * Dover Corp  DOV.N : Credit Suisse initiates coverage with outperform rating and $171 PT
     * Teledyne Technologies  TDY.N : Credit Suisse initiates with outperform rating; $503 PT
     * Zebra Technologies Corp  ZBRA.O : Credit Suisse initiates with outperform rating; $319 PT
 Following is a summary of research actions on U.S. companies reported by Reuters on Tuesday.
Stock entries are in alphabetical order.  
     * AGCO Corp  AGCO.N : JP Morgan raises target price to $155 from $135
     * Amgen Inc  AMGN.O : Piper Sandler raises target price to $299 from $297
     * Amphenol Corp  APH.N : Credit Suisse initiates coverage with outperform rating; $93 PT
     * Braze Inc  BRZE.O : JP Morgan cuts target price to $38 from $47
     * Brookfield Corp  BN.N : Credit Suisse cuts target price to $42 from $50
     * Cognex Corp  CGNX.O : Credit Suisse initiates coverage with underperform rating; $41 PT
     * Coupa Software Inc  COUP.O : JP Morgan raises target price to $81 from $62
     * Coupa Software Inc  COUP.O : RBC raises to sector perform from underperform
     * Coupa Software Inc  COUP.O : RBC raises target price to $81 from $55
     * Custom Truck One Source Inc  CTOS.N : JP Morgan initiates with neutral rating and $7.5 PT
     * Dover Corp  DOV.N : Credit Suisse initiates coverage with outperform rating and $171 PT
     * Edwards Lifesciences Corp  EW.N : Raymond James cuts target price to $83 from $85
     * Entergy Corp  ETR.N : JP Morgan raises target price to $140 from $126
     * Fate Therapeutics Inc  FATE.O : SVB Securities cuts target price to $62 from $64
     * Fate Therapeutics Inc  FATE.O : Truist Securities cuts target price to $46 from $51
     * Insulet Corp  PODD.O : Baird raises target price to $340 from $315
     * Keros Therapeutics Inc  KROS.O : BTIG raises target price to $105 from $95
     * Mirati Therapeutics Inc  MRTX.O : Piper Sandler raises target price to $87 from $84
     * Novo Nordisk  NVO.N : Cowen and Company raises target price to $145 from $130
     * Oracle Corp  ORCL.N : JP Morgan raises target price to $87 from $84
     * Oracle Corp  ORCL.N : Piper Sandler raises target price to $85 from $75
     * Realty Income Corp  O.N : JP Morgan cuts target price to $71 from $73
     * Sarcos Technology and Robotics  STRC.O : Credit Suisse initiates with neutral rating; $4 PT
     * Teledyne Technologies  TDY.N : Credit Suisse initiates with outperform rating; $503 PT
     * Tyler Technologies Inc  TYL.N : Baird cuts target price to $440 from $460
     * Udemy Inc  UDMY.O : Baird cuts target price to $16 from $20
     * Ultragenyx Pharmaceutical Inc  RARE.O : JP Morgan cuts target price to $77 from $128
     * Usertesting Inc  USER.N : Piper Sandler cuts to neutral from overweight
     * Veris Residential Inc  VRE.N : BTIG cuts target price to $22 from $26
     * Vontier Corp  VNT.N : Credit Suisse initiates coverage with neutral rating; $21 target 
     * Zebra Technologies Corp  ZBRA.O : Credit Suisse initiates with outperform rating; $319 PT
 (Compiled by Bengaluru Newsroom)
 ((Diaries@thomsonreuters.com))